Skip to content
CancerIndex

Publication

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Authors not recorded

Blood2017PMID 28588020PMC5572791stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (4)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 4

Curated evidence

Evidence citing this paper (2)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
28588020
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
IDH2 Mutation2
EnasidenibAcute Myeloid LeukemiaCURATED_BROADERPredictiveASupports Sensitivity Response4accepted
EID5069

A first-in-human phase 1/2 trial assessing the pharmacology, safety and activity of Enasidenib in IDH2-mutant myeloid hematoblastosis patients. In the AML subgroup (n=176, (n=130 R140; n=45 R172; n=1 … (full text at CIViC)

PMID 28588020 · Stein et al., 2017 · Open in CIViC

civic
〃Acute Myeloid LeukemiaCURATED_BROADERPredictiveASupports Sensitivity Response3rejected
EID7279

In phase 1/2 trial for patients with relapsed or refractory AML with IDH2 mutation were treated with enasidenib. Overall response rate was 40.3%, with a median response duration was 5.8 months, median… (full text at CIViC)

PMID 28588020 · Stein et al., 2017 · Open in CIViC

civic